Crossmark

Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib

Crossref DOI link: https://doi.org/10.1007/s00280-018-3547-2

Published Online: 2018-03-12

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deng, Mengyan https://orcid.org/0000-0001-9824-7543
Li, Linna

Zhao, Jianchun

Yuan, Shoujun

Li, Wenbao
Funding

Funding for this research was provided by:

“Zhufeng Scholar Program” of Ocean University of China (841412016)

“Major Projects of Independent Innovation” of Qingdao (15-4-13-zdzx-hy)

“Outstanding Talents Plan” of Qingdao (15-10-3-15-(34)-zch)

Aoshan Talents Cultivation Program of Qingdao National Laboratory for Marine Science and Technology (No.2017ASTCP-OS08)

National Natural Science Foundation of China (NSFC 81472687 and 81773761)

youth special fund for PhD of Qingdao (No.16-5-1-62-jch)
License Information

Text and Data Mining valid from 2018-03-12
More Information

Article History

Received: 9 December 2017

Accepted: 20 February 2018

First Online: 12 March 2018

Compliance with ethical standards

:

: All authors declare that there is no conflict of interest.

: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.